Key result
Pioglitazone is linked to a ~31% increase in plasma hANP levels in type 2 diabetes.
Why the study?
Does pioglitazone-induced pretibial edema correlate with plasma hANP levels in patients with type 2 diabetes?
Population
49 patients with type 2 diabetes and no history of pretibial edema (mean age 64+/-12 years, 34 men, 15 women).
Design
Cohort
Follow-up
3 months
Authors
Loading...
Higher hANP associated with pioglitazone-induced pretibial edema; leaves open whether baseline levels predict volume overload in larger cohorts.
Observational (n=49)
Does pioglitazone-induced pretibial edema correlate with plasma hANP levels in patients with type 2 diabetes?
Absolute Event Rate: 26% vs 19.8%
p-value: p=0.0020
Higher baseline and on-treatment plasma hANP levels may predict the development of pretibial edema in type 2 diabetic patients treated with low-dose pioglitazone.
Kahara et al. (2005) conducted an observational in Type 2 diabetes (n=49). Pioglitazone vs. Baseline was evaluated on Plasma hANP level (pg/ml) (p=0.0020). Pioglitazone treatment for 3 months significantly increased plasma hANP levels from 19.8 to 26.0 pg/ml (p=0.0020) in patients with type 2 diabetes.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: